Search Videos and More
News
Dana-Farber’s Judy Garber Is Recipient Of Brinker Award For Scientific Distinction
This year’s Brinker Award for Scientific Distinction in Clinical Research is being presented today to Judy Garber, M.D., M.P.H., Chief of the Division of Cancer Genetics and Prevention at Dana Farber Cancer Institute.
News
Tamoxifen May Boost PI3K Signaling to Increase Uterine Cancer Risk in Some Patients
Uterine cancers that developed in patients treated with tamoxifen had fewer PI3K pathway mutations and may have instead been driven by tamoxifen-induced PI3K pathway activation, according to results presented at the 2021 San Antonio Breast Cancer Symposium.
News
Implantable Device Helps Predict Drug Therapy Efficacy
Dana-Farber investigators recently launched a trial of a miniature device that can be implanted into ovarian tumors to deliver microdoses of different drugs, with the goal of rapidly measuring their effectiveness in killing cancer cells.
Document
ASH 2021 Featured Oral Presentations
The Annual Meeting of the American Society of Hematology (ASH) will take place December 11-14th. To keep-up with latest advances, the live schedule of oral presentations by Dana-Farber faculty is attached for your convenience.
News
Targeted Drug Combination Shows Unprecedented Activity in Some Highly Aggressive Brain Tumors
Treatment with dabrafenib and trametinib yielded encouraging rate of durable responses in both high-grade and low-grade brain tumors carrying the rare BRAF v600E mutation. Study is first to show benefit of any targeted drugs in glioblastomas – the most aggressive brain tumor.
News
Discovery May Lead to Expanded Donor Pool for Stem Cell Transplants for Patients with Cancer
Researchers find that in many cases people with a condition known as clonal hematopoiesis can safely serve as stem cell transplant donors.
News
Dana-Farber Research Supports FDA Approval of Immunotherapy Drug Given After Surgery for Certain Patients with Kidney Cancer
Pembrolizumab is the first drug approved as adjuvant therapy for patients with kidney cancer considered at high risk of relapse.
News
Venetoclax Shown to Benefit Patients with Waldenström Macroglobulinemia, Including Some Who Relapsed After Previous Therapy
A drug that strips cancer cells of their quest for immortality represents an effective new option for patients with Waldenström macroglobulinemia, including those not helped by the only class of drugs currently approved to treat the disease, a clinical trial by Dana-Farber Cancer Institute investigators demonstrates.
News
Dana-Farber Cancer Institute Faculty Among World’s Most Highly Cited Researchers
Dana-Farber Cancer Institute is proud to announce that 35 of its researchers have been named to the Highly Cited Researchers list of 2021 released today by the Institute for Scientific Information at Clarivate.
News
Papers Recount How Research Labs Learned to Work in Four-Part Harmony
A quartet of recent papers in the journal Clinical Cancer Research put the behind-the-scenes efforts involved in a major Moonshot project squarely on the record. The papers provide an inside look at some of the essential start-up activities of the Cancer Immune Monitoring and Analysis Centers and Cancer Immunologic Data Commons (CIMAC-CIDC), a network of laboratories and a bioinformatics center established to perform the analytic work involved in developing new immunotherapies for cancer.
News
Survival Similar for Younger and Older Patients with Metastatic Colorectal Cancer, Study Finds
Even though young patients with metastatic colorectal cancer tend to be more fit and receive more intensive treatment than older patients, both groups survive for roughly the same amount of time, according to a new study by Dana-Farber Cancer Institute investigators.
News
Immunotherapy May Yield Longer Treatment-Free Survival than Targeted Therapy in Advanced Renal Cell Carcinoma Patients
Analysis uses novel endpoint of treatment-free survival (TFS) to ‘better balance the efficacy and toxicity to patients’